MARKET

ILMN

ILMN

Illumina Inc
NASDAQ
117.30
+1.01
+0.87%
After Hours: 116.39 -0.91 -0.78% 19:00 07/25 EDT
OPEN
116.34
PREV CLOSE
116.29
HIGH
121.62
LOW
115.95
VOLUME
1.55M
TURNOVER
0
52 WEEK HIGH
195.64
52 WEEK LOW
86.49
MARKET CAP
18.69B
P/E (TTM)
-14.3868
1D
5D
1M
3M
1Y
5Y
1D
Watchman In Focus As Boston Scientific Reports Its Q2
NASDAQ · 2d ago
Illumina: Strengthening Competitive Position, Relevance And A Very Compelling Valuation
Illumina is the leader in genomic sequencing. Its acquisition of GRAIL, the first multi-cancer early detection screening technology, has been criticized for being anti-competitive. The company's core genetic sequencing business has suffered a slowdown due to the COVID pandemic. But the company's relevance and competitive position is only strengthening.
Seeking Alpha · 3d ago
Ensemble Capital Management Q2 2024 Letter
In the first half of 2024, Ensemble Capital Management's investment strategy was up 8.02% while the S&P 500 was up 15.29%. The average stock within the S &P 500 is only up 5.07% so far this year. We believe investors are correctly recognizing the potential of artificial intelligence.
Seeking Alpha · 4d ago
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
NASDAQ · 4d ago
BUZZ-10x Genomics advances after Jefferies upgrades to 'buy'
10x Genomics' TXG.O shares gain 6.5% to $17.79 premarket. Brokerage Jefferies upgrades to "buy" from "hold" on longer term confidence in company's single-cell research unit. Medical equipment maker's TGX technology superior vs competitors, brokerage says.
Reuters · 4d ago
Weekly Report: what happened at ILMN last week (0715-0719)?
Weekly Report · 4d ago
Oracle CEO Safra Catz to depart Walt Disney board
Oracle CEO Safra Catz to depart Walt Disney board after six years. Catz was elected to Disney's board in 2017. Disney CEO Robert Iger says Catz has provided invaluable insight to the entertainment company's strategic planning. Following Catz's departure, Walt Disney will be down to 11 members.
Reuters · 07/19 21:18
Patient Capital Management Q2 2024 Investment Review
Seeking Alpha · 07/18 16:45
More
About ILMN
Illumina, Inc. is engaged in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Its products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Its product categories include Instruments, Kits & Reagents, Selection Tools, and Software & Analysis. Its Instruments category include sequencing platforms, microarray scanners, and IVD instruments. Its Kits & Reagents category consists of library preparation kits, sequencing reagents, microarray kits, clinical research products, and IVD products. Its Selection Tools category include Library Prep & Array Kit Selector, Gene Panel & Array Finder, DesignStudio Custom Assay Designer, and other. Its services include sequencing services, microarray services, proactive instrument monitoring, and instrument services and training. It is also a developer of an emerging and highly differentiated single-cell technology.

Webull offers Illumina Inc stock information, including NASDAQ: ILMN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ILMN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ILMN stock methods without spending real money on the virtual paper trading platform.